NASDAQ:AVEO

AVEO Pharmaceuticals Competitors

$6.25
-0.02 (-0.32 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.03
Now: $6.25
$6.32
50-Day Range
$6.21
MA: $8.47
$15.28
52-Week Range
$3.60
Now: $6.25
$18.24
Volume605,021 shs
Average Volume2.26 million shs
Market Capitalization$169.56 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4

Competitors

AVEO Pharmaceuticals (NASDAQ:AVEO) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying AVEO stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to AVEO Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

AVEO Pharmaceuticals (NASDAQ:AVEO) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

33.7% of AVEO Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 4.5% of AVEO Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

AVEO Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares AVEO Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVEO Pharmaceuticals-483.99%-103.66%-48.01%
Amgen29.42%95.55%15.52%

Earnings & Valuation

This table compares AVEO Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVEO Pharmaceuticals$28.80 million5.89$9.39 million$0.6110.25
Amgen$23.36 billion6.39$7.84 billion$14.8217.49

Amgen has higher revenue and earnings than AVEO Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for AVEO Pharmaceuticals and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVEO Pharmaceuticals00503.00
Amgen091402.61

AVEO Pharmaceuticals currently has a consensus price target of $17.80, suggesting a potential upside of 184.80%. Amgen has a consensus price target of $261.1429, suggesting a potential upside of 0.77%. Given AVEO Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe AVEO Pharmaceuticals is more favorable than Amgen.

Summary

Amgen beats AVEO Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

AVEO Pharmaceuticals (NASDAQ:AVEO) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

33.7% of AVEO Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 4.5% of AVEO Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

AVEO Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Profitability

This table compares AVEO Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVEO Pharmaceuticals-483.99%-103.66%-48.01%
Gilead Sciences5.48%37.77%12.76%

Earnings & Valuation

This table compares AVEO Pharmaceuticals and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVEO Pharmaceuticals$28.80 million5.89$9.39 million$0.6110.25
Gilead Sciences$22.45 billion3.72$5.39 billion$6.1410.81

Gilead Sciences has higher revenue and earnings than AVEO Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for AVEO Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVEO Pharmaceuticals00503.00
Gilead Sciences191302.52

AVEO Pharmaceuticals currently has a consensus price target of $17.80, suggesting a potential upside of 184.80%. Gilead Sciences has a consensus price target of $97.68, suggesting a potential upside of 47.51%. Given AVEO Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe AVEO Pharmaceuticals is more favorable than Gilead Sciences.

Summary

Gilead Sciences beats AVEO Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

AVEO Pharmaceuticals (NASDAQ:AVEO) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

33.7% of AVEO Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 4.5% of AVEO Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

AVEO Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares AVEO Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVEO Pharmaceuticals-483.99%-103.66%-48.01%
Vertex Pharmaceuticals38.51%28.55%20.68%

Earnings & Valuation

This table compares AVEO Pharmaceuticals and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVEO Pharmaceuticals$28.80 million5.89$9.39 million$0.6110.25
Vertex Pharmaceuticals$4.16 billion13.69$1.18 billion$4.2951.32

Vertex Pharmaceuticals has higher revenue and earnings than AVEO Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for AVEO Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVEO Pharmaceuticals00503.00
Vertex Pharmaceuticals042112.88

AVEO Pharmaceuticals currently has a consensus price target of $17.80, suggesting a potential upside of 184.80%. Vertex Pharmaceuticals has a consensus price target of $293.2083, suggesting a potential upside of 33.24%. Given AVEO Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe AVEO Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Summary

Vertex Pharmaceuticals beats AVEO Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

AVEO Pharmaceuticals (NASDAQ:AVEO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

33.7% of AVEO Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 4.5% of AVEO Pharmaceuticals shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

AVEO Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Profitability

This table compares AVEO Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVEO Pharmaceuticals-483.99%-103.66%-48.01%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Earnings & Valuation

This table compares AVEO Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVEO Pharmaceuticals$28.80 million5.89$9.39 million$0.6110.25
Regeneron Pharmaceuticals$7.86 billion6.87$2.12 billion$21.4723.49

Regeneron Pharmaceuticals has higher revenue and earnings than AVEO Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for AVEO Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVEO Pharmaceuticals00503.00
Regeneron Pharmaceuticals051412.80

AVEO Pharmaceuticals currently has a consensus price target of $17.80, suggesting a potential upside of 184.80%. Regeneron Pharmaceuticals has a consensus price target of $644.1739, suggesting a potential upside of 27.70%. Given AVEO Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe AVEO Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats AVEO Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

AVEO Pharmaceuticals (NASDAQ:AVEO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

33.7% of AVEO Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 4.5% of AVEO Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

AVEO Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares AVEO Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVEO Pharmaceuticals-483.99%-103.66%-48.01%
Biogen35.63%51.00%23.54%

Earnings & Valuation

This table compares AVEO Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVEO Pharmaceuticals$28.80 million5.89$9.39 million$0.6110.25
Biogen$14.38 billion2.89$5.89 billion$33.578.14

Biogen has higher revenue and earnings than AVEO Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than AVEO Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for AVEO Pharmaceuticals and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVEO Pharmaceuticals00503.00
Biogen5141202.23

AVEO Pharmaceuticals currently has a consensus price target of $17.80, suggesting a potential upside of 184.80%. Biogen has a consensus price target of $303.3103, suggesting a potential upside of 11.07%. Given AVEO Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe AVEO Pharmaceuticals is more favorable than Biogen.

Summary

Biogen beats AVEO Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

AVEO Pharmaceuticals (NASDAQ:AVEO) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for AVEO Pharmaceuticals and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVEO Pharmaceuticals00503.00
Alexion Pharmaceuticals017412.27

AVEO Pharmaceuticals currently has a consensus price target of $17.80, suggesting a potential upside of 184.80%. Alexion Pharmaceuticals has a consensus price target of $153.4286, suggesting a potential downside of 7.87%. Given AVEO Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe AVEO Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Volatility & Risk

AVEO Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Institutional and Insider Ownership

33.7% of AVEO Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.5% of AVEO Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares AVEO Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVEO Pharmaceuticals-483.99%-103.66%-48.01%
Alexion Pharmaceuticals16.32%23.16%14.76%

Earnings & Valuation

This table compares AVEO Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVEO Pharmaceuticals$28.80 million5.89$9.39 million$0.6110.25
Alexion Pharmaceuticals$4.99 billion7.37$2.40 billion$9.7417.10

Alexion Pharmaceuticals has higher revenue and earnings than AVEO Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats AVEO Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Ad Investing Trends
The Hottest Sector You're Not Watching
With all eyes on EV, tech, and crypto… Even the sharpest of investors are missing this hidden pocket of opportunity in an industry on the brink of exploding

AVEO Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$259.14-1.2%$147.39 billion$23.36 billion20.90Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.38-0.6%$83.03 billion$22.45 billion68.43Analyst Report
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$220.16-0.4%$56.73 billion$4.16 billion27.80Analyst Report
Analyst Revision
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$504.42-0.9%$54.04 billion$7.86 billion18.44Analyst Report
Biogen logo
BIIB
Biogen
1.9$273.20-1.5%$41.62 billion$14.38 billion9.04Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$166.54-0.6%$36.79 billion$4.99 billion38.91News Coverage
Seagen logo
SGEN
Seagen
1.7$144.76-0.5%$26.11 billion$916.71 million56.99Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.62-1.5%$21.56 billion$876.29 million-56.84Analyst Upgrade
Incyte logo
INCY
Incyte
1.7$84.57-2.2%$18.17 billion$2.16 billion-53.87
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$136.03-1.0%$16.12 billion$219.75 million-17.37Analyst Report
Novavax logo
NVAX
Novavax
1.4$208.15-6.4%$15.37 billion$18.66 million-39.88Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.45-0.2%$14.47 billion$1.70 billion18.18Analyst Report
News Coverage
Repligen logo
RGEN
Repligen
1.5$211.99-0.0%$11.61 billion$270.24 million258.52Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$207.58-1.8%$9.08 billion$1.45 billion19.64
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.16-1.4%$8.97 billion$788.10 million103.40Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Exelixis logo
EXEL
Exelixis
1.9$24.51-3.1%$7.65 billion$967.78 million51.06Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.83-1.6%$6.71 billion$195.99 million292.69
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.16-3.0%$5.63 billion$1.12 billion85.75Analyst Report
Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.76-2.1%$3.94 billion$806.43 million-9.46Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.62-3.4%$3.64 billion$1.11 billion21.10News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.16-0.5%$3.19 billion$1.17 billion-43.83Analyst Revision
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.29-1.1%$3.12 billion$36.13 million-67.60
OPKO Health logo
OPK
OPKO Health
1.9$4.13-1.7%$2.77 billion$901.90 million-22.94
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.78-1.2%$2.62 billion$182.24 million-8.50Analyst Upgrade
Insider Selling
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$146.76-0.5%$2.43 billion$120.28 million-148.24Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$26.61-2.3%$2.05 billion$638.60 million-10.23
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.11-3.6%$2.04 billion$48.83 million-14.62
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$126.33-4.1%$1.94 billionN/A-11.41News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.66-0.5%$1.71 billion$428.41 million15.45Analyst Upgrade
News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.53-1.9%$1.63 billion$102.43 million-19.22Analyst Upgrade
Codexis logo
CDXS
Codexis
1.3$22.89-1.4%$1.47 billion$68.46 million-65.40Analyst Report
News Coverage
Gap Up
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.32-1.2%$1.44 billion$82.27 million-17.85News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.98-0.8%$1.21 billion$261.02 million6.11
MannKind logo
MNKD
MannKind
1.4$4.23-1.7%$1.04 billion$63.04 million-20.14Increase in Short Interest
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.94-21.8%$1.01 billion$35.22 million-6.53Gap Up
Curis logo
CRIS
Curis
1.3$9.82-5.0%$943.56 million$10 million-11.98News Coverage
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.67-2.0%$937.69 million$3.57 million-10.61
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.55-0.7%$902.28 million$227.19 million45.97Analyst Downgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.34-0.2%$882.77 millionN/A0.00
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88-0.8%$698.67 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17-0.9%$675.74 million$150,000.00-4.53News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.80-2.9%$666.59 million$252 million-2.13
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.67-1.9%$604.18 million$143.01 million-1.08
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55-2.3%$591.17 million$59.29 million-23.67Increase in Short Interest
News Coverage
Agenus logo
AGEN
Agenus
1.6$2.67-4.1%$523.99 million$150.05 million-2.45
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.96-4.1%$464.67 million$22.27 million-3.90Analyst Revision
News Coverage
Verastem logo
VSTM
Verastem
1.3$2.71-0.4%$463.50 million$17.46 million-1.92
Geron logo
GERN
Geron
1.4$1.40-0.0%$445.94 million$460,000.00-4.00Decrease in Short Interest
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.91-0.7%$444.27 million$109.33 million-2.14
XOMA logo
XOMA
XOMA
1.5$35.44-1.6%$405.40 million$18.37 million-31.93Increase in Short Interest
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.